|
Patent landscape, scope, and claims: |
Patent 8,754,096 Scope and Claims: What the US Claims Cover, How Broad They Are, and Where Generics or Licensees Face IP Barriers
US Patent 8,754,096 is a US compound and use estate that is drafted around a Formula I chemical scaffold plus pharmaceutically acceptable salts, with downstream independent coverage that adds pharmaceutical compositions (inert carrier) and methods of treating headache/migraine. The core strength is the Markush-style breadth in substituent selection for multiple positions and a structural “except that” constraint designed to keep at least a defined level of halogenation (F/Cl/Br) in most embodiments. The downstream weakness is that multiple claims are composition and method wrappers that often overlap with other, narrower patents in the same family, depending on the drug product and indication strategy.
What patents protect the compounds of US 8,754,096 (Formula I) in the US?
Direct protection in US 8,754,096 is claim-based and structurally defined. The independent claim is the Formula I compound with extensive substituent ranges, followed by narrower dependent claims that pin down specific structural sub-sets and then use/composition claims that tether treatment to those covered compounds.
Claim set map (US 8,754,096)
- Claim 1 (independent): Formula I compound (or pharmaceutically acceptable salt) with multiple substituent variables X, R1-R7, plus halogenation constraints.
- Claims 2–14 (dependent): Narrow specific X variants, specific R1 lists, and specific combinations for R2-R7 constraints (including special F/Cl/Br/“at least three fluorines” conditions).
- Claims 15, 19, 31, 34 (composition): “A pharmaceutical composition” with inert carrier and the claimed compound.
- Claims 16–17, 20, 23, 26, 29, 32, 35 (methods):
- headache (general) and migraine (specific) treatment methods.
- Claims 18, 21, 24, 27, 30, 33 (additional compound lists):
- These are effectively enumerated exemplars that fall inside the Formula I universe, but are claimed again as their own compound selections.
Core scaffold breadth in Claim 1
Claim 1 is a Markush claim that includes:
- X:
- —C(R8)═ or —N═
- R8 ∈ {H, F, CN}
- R1:
- ∈ {C1–4alkyl, cyclopropylmethyl, cyclobutylmethyl, [1-(trifluoromethyl)cyclopropyl]methyl}
- optionally substituted with F and/or hydroxy
- R2: ∈ {H, methyl}
- R3 (conditional when R2 = H): ∈ {H, F, Cl}
- R4: ∈ {H, F, Cl}
- R5: ∈ {H, F}
- R6: ∈ {H, F}
- R7: ∈ {H, F, Cl} (but subject to additional restrictions below)
The halogenation “except that” constraints are the main limiter
Claim 1 uses several stacked constraints:
-
Global F/Cl requirement unless R3 = F
- Default rule: at least two of R3, R4, R6, R7 must be F or Cl
- Exception: if R3 is F, then R4, R6, R7 may be all hydrogen.
-
If R4 is Cl then R7 cannot be Cl
- This is an anti-symmetry constraint that reduces the “Cl-rich” region of the space.
-
R2 = methyl changes what is allowed for R3
- When R2 is methyl, R3 ∈ {H, methyl, F, Cl, Br}
-
If R5 is F then a stronger fluorination requirement applies
- At least three of R3, R4, R6, R7 must be F (when R5 = F).
-
If R4 is methyl or Cl then R7 cannot be methyl or Cl
- This is a second anti-branching rule that blocks certain “dense halogen or methyl” patterns at the R7 position when R4 carries methyl or Cl.
Practical effect: Claim 1 covers a wide combinatorial chemical space but filters out “too little halogenation” for most embodiments, while allowing a narrow carveout when R3 = F.
How many distinct chemical embodiments does Claim 1 cover?
Claim 1 is broad, but the “except that” clauses reduce the full Cartesian product. Even without enumerating every allowed combination, the parameterization indicates the claim covers:
- Two main X classes (C= with R8 options vs N=)
- Multiple R1 chemotypes with optional F/hydroxy substitution
- Binary R2
- Multi-valued R3-R7 with conditional allowances
- At least two halogen/fluoro/chloro constraints that apply in most (not all) cases
Example subspace expansion (structural logic)
- X branch count: 2 structural types × R8 options (H/F/CN) → up to 6 substitution patterns.
- R1: 4 chemotypes × optional substitution with F/hydroxy up to 3 substituents (depending on what “as allowed by valence” permits for each chemotype).
- R2: 2 options
- R3-R7: several conditional domains:
- R2 = H: R3 ∈ {H,F,Cl}; R4 ∈ {H,F,Cl}; R6 ∈ {H,F}; R7 ∈ {H,F,Cl} with constraints.
- R2 = methyl: R3 expands to include methyl and Br; R4 includes methyl in dependent logic while Claim 1 text includes methyl among R4 allowed when R2=methyl (via “R4 is selected from hydrogen, methyl, F or Cl”); additional restrictions apply to R7.
The result is an estate that is typically more defensible against “design-around” than a single fixed molecule, because infringement can be argued over many substitution variants without needing identity to a single embodiment.
Which specific compounds are explicitly enumerated in US 8,754,096?
US 8,754,096 includes additional compound-selection claims that function as a “short list” of representative embodiments already within the Formula I scope. The claim text provided enumerates two groups.
Enumerated group in Claim 30
Claim 30 lists a set of structures by aromatic identity/substitution and ring/side-chain identity. The list includes:
- Ar = 2-fluorophenyl
- Ar = 2-chlorophenyl
- Ar = 3-methylphenyl
- Ar = 2,3-difluorophenyl
- Ar = 2,3,5-trifluorophenyl
- Ar = 2-chloro-6-fluorophenyl
- Ar = 2,6-dichlorophenyl
- Ar = 2,3-dichlorophenyl
- Ar = 2,3,6-trifluorophenyl
- Ar = 2,3,5,6-tetrafluorophenyl
- Ar = 3-fluoro-2-methylphenyl
- Each paired with “R2 Ar H” style variable formatting in the claim text
- plus pharmaceutically acceptable salts
Enumerated group in Claim 33
Claim 33 lists ring-sidechain combinations:
- cyclobutylmethyl substituted variants with 2,3-difluorophenyl and 2-fluorophenyl
- isopropyl variants with 2-fluorophenyl
- (2S)-3,3,3-trifluoro-2-hydroxypropyl variant with 2,3-difluorophenyl
- and corresponding pharmaceutically acceptable salts
Infringement signaling
These enumerated claims matter in practice because they:
- allow enforcement with a direct mapping to specific exemplars even if a downstream accused compound is argued to land outside the strictest interpretation of the broader Markush language; and
- support settlement leverage: defendants can be forced to clear both broad and exemplar-specific tiers.
What formulation patents does US 8,754,096 cover (and what does it not)?
US 8,754,096 includes composition-inert-carrier claims:
- Claim 15: inert carrier + compound of Claim 1
- Claim 19: inert carrier + compound of Claim 18
- Claim 31: inert carrier + compound of Claim 30
- Claim 34: inert carrier + compound of Claim 33
Scope: These are generic “formulation” claims that protect the drug product as a combination of:
- the specific compound (or the listed compound selection tier), and
- an inert carrier.
Scope limitation: They do not, on the claim text provided, include:
- specific release profiles (IR/ER),
- specific dosage forms (tablet vs nasal vs injectable),
- or specific manufacturing parameters.
That typically means other patents in the family (not provided here) may cover the actual commercial product form and process, while US 8,754,096 can act as a baseline chemical-use and composition blocker.
When does exclusivity end for US 8,754,096?
No exclusivity timeline can be produced from the claim text alone. US patent term and exclusivity depend on:
- filing date(s),
- priority chain,
- PTA adjustments,
- patent expiry jurisdiction,
- and the regulatory exclusivity regime for the specific FDA application.
If you need term-to-market mapping, that requires bibliographic data for US 8,754,096 and its linked FDA reference product. Without those facts, no accurate exclusivity or “generic launch window” can be stated.
How strong is the patent estate for migraine compounds like those in US 8,754,096?
Based on claim architecture alone, US 8,754,096 is strong in three ways:
- Broad Markush compound claim (Claim 1): multiple degrees of freedom across X, R1-R7.
- Specific narrow dependent claims (2–14): multiple “pin” points on likely design-around pressure zones:
- X class switching (—N═ vs —C(R8)═),
- R1 chemotype narrowing to named substituents,
- and constraint-based halogenation patterns (notably R5=F and “three of R3/R4/R6/R7 must be F”).
- Multiple claim types anchored to the same scaffold:
- compositions (inert carrier),
- methods for headache and migraine.
Main weakness from a litigation strategy perspective: if the accused product differs by a single element that courts treat as limiting (for example, an X geometry, R8 value, or a specific halogenation constraint), defendants can try to fall outside Claim 1 while still being captured by narrower dependent claims only if those dependent claim elements match.
What patent litigation risk exists under US 8,754,096 for generic or biosimilar entrants?
Biosimilars are not the typical risk category for a small-molecule Formula I compound patent.
The enforcement risk is instead:
- Paragraph IV filings against the reference product if an Orange Book listing exists that ties the reference to US 8,754,096; and/or
- non-Paragraph IV infringement assertions based on product formulation and method of use activities.
Risk driver in Claim 1: a generic drug that uses a non-infringing chemical scaffold may still face infringement if:
- its chemical structure lands within the Markush range by literal interpretation; and
- it includes a pharmaceutically acceptable salt form covered by the claim.
Risk driver in method claims: if an ANDA label instructs or encourages migraine/headache treatment with a compound within the claim scope, method-of-use exposure can become more acute. Many settlements also attempt to manage labeling as a workaround if the chemical itself can’t be designed around easily.
Does US 8,754,096 cover method-of-use labeling beyond “migraine”?
The provided independent and dependent method claims are:
- Claim 16: treating headache
- Claim 17: headache is migraine
- Claim 20: treating migraine
- Claims 23, 26, 29, 32, 35: treating migraine using compounds tied to different tiers (Claims 21, 24, 27, 30, 33)
Practical scope: the method claims cover migraine treatment as a mammalian use and are likely designed to support FDA labeling disputes when a generic seeks “migraine indication” carveouts.
Design-around angle: if a generic were to launch without that therapeutic instruction, method-of-use risk could be reduced, but infringement analysis depends on the legal standard applied to induced/direct infringement and the exact label wording.
How does US 8,754,096 compare to typical migraine small-molecule patent strategies?
Relative to many migraine estates, US 8,754,096 has:
- more chemical scope per claim (broad substituent Markush core), and
- a direct migraine use hook in the same patent.
Many competitor portfolios split these into:
- one patent for a chemical class,
- separate patents for specific polymorphs/formulations,
- and separate patents for use and dosing.
Here, composition (inert carrier) and migraine methods appear in the same document, giving the holder multiple enforcement levers in a single asserted family member.
Key Takeaways
- US 8,754,096 Claim 1 is a broad Markush Formula I compound claim with multi-position substituent variability across X, R1, R2, R3-R7 plus halogenation constraints that eliminate some low-halogen patterns while allowing limited carveouts.
- Dependent claims 2–14 tighten enforcement around specific X classes, specific R1 chemotypes, and specific halogen/methyl fluorination patterns, including a notable “if R5 is F then at least three of R3/R4/R6/R7 must be F” constraint.
- The patent also covers “inert carrier” compositions and migraine/headache methods, creating multiple infringement theories that can be used in parallel (chemical, formulation, labeling/use).
- The provided claim text alone is insufficient to compute exclusivity end dates, Orange Book status, or Paragraph IV/litigation timelines for US 8,754,096.
FAQs
-
Does changing X from —N═ to —C(R8)═ avoid US 8,754,096?
Not automatically, because Claim 1 explicitly covers both X classes, with R8 restricted to H/F/CN.
-
If an accused compound has low fluorine/chlorine on R3/R4/R6/R7, is it outside Claim 1?
Often yes, because Claim 1 requires at least two of R3/R4/R6/R7 to be F or Cl except when R3 is F.
-
Is the “R4 is Cl then R7 cannot be Cl” rule a meaningful design-around lever?
Yes. It blocks a subset of Cl-rich embodiments and can be used to argue non-infringement if the accused structure matches that forbidden pairing.
-
Do the inert-carrier composition claims require a particular dosage form?
The provided claims do not specify dosage form, so they are framed broadly as compound plus inert carrier.
-
Can labeling carveouts reduce risk from the migraine method claims?
Potentially, because the method claims are indication-specific, but risk depends on how the ANDA label is drafted and how infringement is evaluated for method-of-use theories.
References
- United States Patent 8,754,096. (Claims excerpt provided in prompt).
More… ↓
⤷ Start Trial
|
